Alan F List

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. ncbi request reprint New approaches to the treatment of myelodysplasia
    Alan F List
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Oncologist 7:39-49. 2002
  2. pmc Valuation of transfusion-free living in MDS: results of health utility interviews with patients
    Agota Szende
    Covance, Leeds, UK
    Health Qual Life Outcomes 7:81. 2009
  3. ncbi request reprint Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS)
    Alan F List
    Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Semin Oncol 32:S31-5. 2005
  4. ncbi request reprint Lenalidomide: an immunomodulatory drug
    Edward Crane
    H Lee Moffitt Cancer Center and Research Institute, and the University of South Florida College of Medicine, Malignancy Hematology Program, Department of Interdisciplinary Oncology, Tampa, FL 33612, USA
    Future Oncol 1:575-83. 2005
  5. ncbi request reprint Efficacy of lenalidomide in myelodysplastic syndromes
    Alan List
    Department of Interdisciplinary Oncology, University of South Florida and the H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    N Engl J Med 352:549-57. 2005
  6. ncbi request reprint Methyltransferase inhibitors: changing the treatment algorithm for myelodysplastic syndromes
    Alan List
    Hematologic Malignancies Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 11:16-9. 2004
  7. ncbi request reprint Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells
    Alan F List
    The H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Exp Hematol 32:526-35. 2004
  8. doi request reprint Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Am J Hematol 87:1006-9. 2012
  9. doi request reprint Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions
    Rami S Komrokji
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Hematol Oncol Clin North Am 24:377-88. 2010
  10. doi request reprint Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome
    Rami S Komrokji
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Blood 120:3419-24. 2012

Detail Information

Publications76

  1. ncbi request reprint New approaches to the treatment of myelodysplasia
    Alan F List
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Oncologist 7:39-49. 2002
    ..The identification of relevant biologic targets in MDS has raised expectations for the development of disease-specific therapies for MDS in the years that follow...
  2. pmc Valuation of transfusion-free living in MDS: results of health utility interviews with patients
    Agota Szende
    Covance, Leeds, UK
    Health Qual Life Outcomes 7:81. 2009
    ..This study measured how myelodysplastic syndrome (MDS) patients value transfusion independence (TI), reduced transfusions (RT) and transfusion-dependence (TD) using health utility assessment methodology...
  3. ncbi request reprint Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS)
    Alan F List
    Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Semin Oncol 32:S31-5. 2005
    ..Multicenter phase II and III studies are under way to further assess the erythroid and cytogenetic response rates in distinct subtypes of MDS, including 5q- deletion, and to optimize its clinical application...
  4. ncbi request reprint Lenalidomide: an immunomodulatory drug
    Edward Crane
    H Lee Moffitt Cancer Center and Research Institute, and the University of South Florida College of Medicine, Malignancy Hematology Program, Department of Interdisciplinary Oncology, Tampa, FL 33612, USA
    Future Oncol 1:575-83. 2005
    ..Further trials are ongoing for many other malignancies. This report will review the preclinical and clinical results of the investigations with this exciting new therapeutic, its toxicities and future prospects...
  5. ncbi request reprint Efficacy of lenalidomide in myelodysplastic syndromes
    Alan List
    Department of Interdisciplinary Oncology, University of South Florida and the H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    N Engl J Med 352:549-57. 2005
    ..In patients with myelodysplastic syndromes and symptomatic anemia, we evaluated the safety and hematologic activity of lenalidomide, a novel analogue of thalidomide...
  6. ncbi request reprint Methyltransferase inhibitors: changing the treatment algorithm for myelodysplastic syndromes
    Alan List
    Hematologic Malignancies Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 11:16-9. 2004
  7. ncbi request reprint Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells
    Alan F List
    The H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Exp Hematol 32:526-35. 2004
    ..To evaluate receptor-selective trophic response to VEGF-A in AML cells, we investigated receptor-specific ligand activation responsible for VEGF-initiated clonogenic response...
  8. doi request reprint Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Am J Hematol 87:1006-9. 2012
    ..8; 95% CI 0.6-0.9; P = 0.004). Our findings indicate that hypoalbuminemia is an independent prognostic biomarker that may serve as a surrogate representative of disease biology or comorbidities in patients with MDS...
  9. doi request reprint Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions
    Rami S Komrokji
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Hematol Oncol Clin North Am 24:377-88. 2010
    ....
  10. doi request reprint Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome
    Rami S Komrokji
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Blood 120:3419-24. 2012
    ..The benefits of lenalidomide plus rhu-EPO are currently under investigation in a phase 3 Eastern Cooperative Oncology Group (ECOG)-sponsored intergroup study. This study is registered at www.clinicaltrials.gov as NCT00910858...
  11. doi request reprint Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Curr Hematol Malig Rep 5:9-14. 2010
    ..This article reviews the clinical experience with lenalidomide, highlighting recent understanding of the dual karyotype-dependent mechanisms of action...
  12. pmc Underreporting of myeloid malignancies by United States cancer registries
    Benjamin M Craig
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Epidemiol Biomarkers Prev 21:474-81. 2012
    ....
  13. doi request reprint Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome
    Celeste Bello
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer 117:1463-9. 2011
    ..The authors evaluated predictive factors in patients with secondary AML treated with anthracycline-based induction therapy...
  14. pmc TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients
    Gisela Caceres
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612
    Proc Natl Acad Sci U S A 110:16127-32. 2013
    ..We conclude that targeted suppression of p53 could support effective erythropoiesis in lenalidomide-resistant del(5q) MDS. ..
  15. doi request reprint Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
    Rami S Komrokji
    Department of Hematological Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Br J Haematol 162:517-24. 2013
    ..In addition, four patients each achieved transfusion independence and haematological improvements. In conclusion, oral rigosertib is bioavailable and well tolerated, and has clinical activity in patients with MDS. ..
  16. doi request reprint Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models
    Vu H Duong
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Leuk Res 37:510-5. 2013
    ..Response rates were comparable to those reported for de novo myelodysplastic syndrome. When we analyzed outcomes according to five scoring systems, only the Global MD Anderson Risk Model predicted survival with statistical significance...
  17. ncbi request reprint Lenalidomide: targeted anemia therapy for myelodysplastic syndromes
    Alan F List
    Malignant Hematology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 13:4-11. 2006
    ..The most common adverse reactions include dose-dependent neutropenia and thrombocytopenia that are more pronounced in patients with del(5q) in whom early suppression of the clone is expected...
  18. doi request reprint Role of lenalidomide in the treatment of myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Semin Oncol 38:648-57. 2011
    ..Finally, we highlight the current understanding of its mechanism of action, discussing the emerging insight into the underlying biology of del(5q) MDS and its linkage to potential targets of lenalidomide...
  19. doi request reprint Emerging immunosuppressive drugs in myelodysplastic syndromes
    Pearlie K Epling-Burnette
    H Lee Moffitt Cancer Center and Research Institute, Immunology Department, SRB 23033, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Expert Opin Emerg Drugs 17:519-41. 2012
    ..In early MDS, cytopenias arise or are exacerbated by humoral and cellular immune-mediators that suppress hematopoietic progenitor survival and alter the bone marrow microenvironment...
  20. pmc Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome
    Adam W Mailloux
    Immunology Department, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Immunol 189:3198-208. 2012
    ..Based on these findings, Treg(EM) cell expansion may be synonymous with human Treg activation and indicate microenvironmental changes conducive to transformation in myelodysplastic syndromes...
  21. ncbi request reprint Lenalidomide for treatment of myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Curr Pharm Des 18:3198-203. 2012
    ..We highlight the mechanism of action and the recent advances in understanding the biology of del (5q) MDS. We also explore its potential use and the efforts to further improve its activity in non-del (5q) MDS...
  22. doi request reprint The 5q- syndrome: biology and treatment
    Eric Padron
    H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Curr Treat Options Oncol 12:354-68. 2011
    ..We discuss herein the current understanding of the biology of the 5q- syndrome, actions of efficacy of lenalidomide and strategies for clinical management...
  23. doi request reprint Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens
    Samantha L Price
    Department of Pharmacy, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Leuk Res 35:301-4. 2011
    ..2% for MEC (P=0.09), with median OS of 11 and 4.5 months, respectively (P=0.07). In first relapse, CR was 36.8% and 25.9% (P=0.35) and median OS was 6.7 and 6.7 months, respectively (P=0.87). Our data support use of CLAG for RR-AML...
  24. doi request reprint Management of lower-risk myelodysplastic syndromes: the art and evidence
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, FOB 3rd Floor, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Curr Hematol Malig Rep 6:145-53. 2011
    ..We use a case-based format to discuss current options for treatment, including erythropoiesis-stimulating agents, hypomethylating agents, lenalidomide, immunosuppressive therapy, supportive care, and investigational agents...
  25. ncbi request reprint Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes
    Alan F List
    Malignant Hematology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 13:12-6. 2006
    ..This discussion examines the current NCCN guidelines for the treatment of these patients, including the management of anemia in lower-risk MDS, and discusses the potential future therapeutic applications of lenalidomide in this disease...
  26. ncbi request reprint New agents in the treatment of MDS
    Alan F List
    Malignant Hematology Division, H Lee Moffitt Cancer Center and Research Institute, USA
    Clin Adv Hematol Oncol 3:832-4. 2005
  27. doi request reprint New therapeutics for myelodysplastic syndromes
    Alan F List
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Leuk Res 36:1470-4. 2012
    ....
  28. doi request reprint Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Cancer 118:2659-64. 2012
    ..We applied the MDAS to Moffitt Cancer Center (MCC) MDS patients to validate its prognostic utility...
  29. ncbi request reprint Immunomodulatory drugs
    Edward Crane
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, and University of South Florida College of Medicine, Tampa 33612, USA
    Cancer Invest 23:625-34. 2005
    ..The evolution of the use of thalidomide as a therapeutic for diseases such as multiple myeloma and myelodysplastic syndrome and the promising initial results of the new IMiDs will be reviewed...
  30. doi request reprint JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth
    Lori N Griner
    Cancer Biology Ph D Program, University of South Florida, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Br J Haematol 160:177-87. 2013
    ..Our study is the first to demonstrate that JAK2-V617F signalling is dependent on lipid rafts and that statins may be effective in a potential therapeutic approach for MPNs...
  31. doi request reprint Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature
    Rahel A Mathew
    University of South Florida, School of Medicine, Tampa, FL, USA
    Leuk Res 36:72-80. 2012
    ..8 months. Overall survival from diagnosis to the last follow-up in patients with LC was 28.2 months, shorter than patients without LC (44 months). LC and its equivalent could predict disease progression to AML...
  32. pmc Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes
    Benjamin M Craig
    Health Outcomes and Behavior, H Lee Moffitt Cancer Center and Research Institute, MRC CANCONT, Tampa, FL 33612 9416, USA
    Leuk Res 35:1453-6. 2011
    ..While most non-registered MDS patients showed resource utilization and survival characteristics consistent with lower-risk MDS, a subset was registered as acute myeloid leukemia (7.6%) and accounted for early mortality...
  33. ncbi request reprint Immunomodulatory therapy for myelodysplastic syndromes
    Lubomir Sokol
    Departmant of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida 33612 9497, USA
    Int J Hematol 86:301-5. 2007
    ..The National Comprehensive Cancer Network Clinical Practice Guidelines recently added lenalidomide to the therapeutic algorithm for MDS as front-line therapy for lower-risk MDS patients with del(5q) and transfusion-dependent anemia...
  34. doi request reprint Biology and treatment of the 5q- syndrome
    Eric Padron
    Hematologic Malignancy Division, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Expert Rev Hematol 4:61-9. 2011
    ..With the emerging data elucidating the pathogenesis of the 5q- syndrome and the success of clinical trials, a cohesive story connecting the biology and pharmacology associated with this subtype of myelodysplastic syndromes has emerged...
  35. ncbi request reprint Lenalidomide in myelodysplastic syndromes
    Alan F List
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Fla, USA
    Clin Adv Hematol Oncol 6:271-2, 311. 2008
  36. ncbi request reprint Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?
    Mikkael A Sekeres
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Curr Hematol Rep 4:182-5. 2005
    ....
  37. ncbi request reprint Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
    Alan List
    University of South Florida College of Medicine and Malignant Hematology Division, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    N Engl J Med 355:1456-65. 2006
    ..We investigated whether lenalidomide (CC5013) could reduce the transfusion requirement and suppress the abnormal 5q31- clone in patients with this disorder...
  38. ncbi request reprint The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes
    Magda Melchert
    Malignant Hematology Division, Department of Medicine, University of South Florida College of Medicine and the H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Curr Opin Hematol 14:123-9. 2007
    ..The aim of this article is to discuss the relevant pathobiologic effects of lenalidomide and the most recent clinical evidence to support its use in patients with myelodysplastic syndrome...
  39. doi request reprint Targeted therapies in myelodysplastic syndrome
    Magda Melchert
    Department of Interdisciplinary Oncology, Malignant Hematology Division, Moffitt Cancer Center and Research Institute, Tampa, FL 33611, USA
    Semin Hematol 45:31-8. 2008
    ..As we continue to collect clinical experience with these agents, the repertoire of available therapeutics for the treatment of MDS will expand and provide a foundation for novel therapeutic combinations...
  40. ncbi request reprint The thalidomide saga
    Magda Melchert
    Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Int J Biochem Cell Biol 39:1489-99. 2007
    ..This review will explore the pharmacokinetic and biologic effects of thalidomide and its progeny compounds...
  41. doi request reprint B-lymphoblastic leukemia/lymphoma associated with t(8;13)(p11;q12)/ ZMYM2 (ZNF198)-FGFR1 : rare case and review of the literature
    Janese Trimaldi
    Department of Pathology, College of Medicine, University of South Florida, Tampa, Fla, USA
    Acta Haematol 130:127-34. 2013
    ..The patient did not respond to hyper-CVAD chemotherapy and within 4 months developed acute myelomonocytic leukemia and expired 11 months after the initial diagnosis. Similar cases from the literature are reviewed. ..
  42. doi request reprint Prognostic factors and risk models in myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Electronic address
    Clin Lymphoma Myeloma Leuk 13:S295-9. 2013
    ..We are learning more about the biology of the disease by uncovering the various genetic and molecular mutations. Those in turn, serve as prognostic factors and will be incorporated in the new risk models. ..
  43. ncbi request reprint Advances in the management of myelofibrosis
    Rami S Komrokji
    Department of Malignant Hematology at the H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33617, USA
    Cancer Control 19:4-15. 2012
    ..Of the MPNs, MF presents with the most severe morbidity and greatest mortality. Although the cause of MF is unknown, it is thought to occur from acquired mutations that target the hematopoietic stem cell...
  44. doi request reprint GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
    Eric Padron
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Blood 121:5068-77. 2013
    ..These preclinical data indicate that GM-CSF signaling inhibitors merit further investigation in CMML and that GM-CSFR expression on myeloid progenitors may be a biomarker for this therapy...
  45. doi request reprint Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome
    Alan F List
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Clin Oncol 30:2134-9. 2012
    ..This 3-year, prospective, multicenter trial assessed the safety and efficacy of deferasirox in low- or intermediate-1-risk myelodysplastic syndrome (MDS)...
  46. ncbi request reprint Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes
    Vishakha Kale
    Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL, USA
    Curr Pharm Biotechnol 7:339-42. 2006
    ..A phase III Intergroup trial (ECOG 2905) will test the capacity to potentiate erythropoietin response by comparing response to lenalidomide monotherapy to the combination of darbepoetin and lenalidomide in non-deletion 5q MDS patients...
  47. ncbi request reprint Developmental therapeutics for myelodysplastic syndromes
    Aung Naing
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL, USA
    J Natl Compr Canc Netw 4:78-82. 2006
    ..The advent of new and effective targeted therapeutics may beneficially affect outcomes of an ever-increasing number of patients with MDS. This discussion summarizes the preliminary results of selected novel therapeutics...
  48. doi request reprint Outcome of patients with myelodysplastic syndromes in the Veterans Administration population
    Rami S Komrokji
    Department of Hematologic Malignancies, H Lee Moffitt Cancer and Research Institute, Tampa, FL 33612, USA
    Leuk Res 34:59-62. 2010
    ..MDS became reportable to the Surveillance, Epidemiology, and End Results Program (SEER) in 2001. We report first study of MDS among large population in the Veteran Affair system...
  49. doi request reprint Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes
    Alan List
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Clin Lymphoma Myeloma 9:S302-4. 2009
    ..Combination strategies are now in both MDS and AML that could further broaden the therapeutic potential of lenalidomide...
  50. pmc A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
    Sheng Wei
    Immunology Program and Malignant Hematology Program, Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Proc Natl Acad Sci U S A 106:12974-9. 2009
    ..These data establish a role for allelic haplodeficiency of the lenalidomide inhibitable Cdc25C and PP2Acalpha phosphatases in the selective drug sensitivity of del(5q) MDS...
  51. ncbi request reprint Immunomodulatory drugs in the treatment of myelodysplastic syndromes
    Jose Ortega
    Department of Interdisciplinary Oncology, University of South Florida, College of Medicine and the H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
    Curr Opin Oncol 19:656-9. 2007
    ..The aim of this article is to discuss the proposed mechanisms of action, clinical trial data, and clinical implications for use of the immunomodulatory drugs in the treatment of myelodysplastic syndrome...
  52. doi request reprint HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1
    Gisela Caceres
    Experimental Therapeutics, Moffitt Cancer Center, University of South Florida, Tampa, Florida 33612, USA
    Cancer Res 72:4204-13. 2012
    ..Taken together, our findings indicate that HG-829 is a potent, long-acting, and noncompetitive modulator of P-glycoprotein export function that may offer therapeutic promise for multidrug-resistant malignancies...
  53. doi request reprint Telomere length in myelodysplastic syndromes
    Dana E Rollison
    Division of Cancer Prevention and Control, Moffitt Cancer Center, Tampa, FL 33612, USA
    Leuk Lymphoma 52:1528-36. 2011
    ..Future studies are needed to further investigate constitutional telomere attrition as a possible predisposing factor for MDS...
  54. ncbi request reprint Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes
    Alan F List
    Malignant Hematology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:29-39. 2008
    ..The current active treatment paradigm for MDS incorporates the most recent strategies yielding improved disease outcomes and patient survival...
  55. pmc Immune dysregulation in myelodysplastic syndrome
    Chiharu Sugimori
    Immunology Program and Malignant Hematology Division, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Hematol Rep 2:e1. 2010
    ..In this review, data accumulated in the US, Europe, and Asia will be summarized to provide insight and direction for a multi-center international trial...
  56. doi request reprint Advancements in the molecular pathogenesis of myelodysplastic syndrome
    Pearlie K Epling-Burnette
    H Lee Moffitt Cancer Center Immunology Program, Tampa, Florida 33612, USA
    Curr Opin Hematol 16:70-6. 2009
    ..The importance of new advances in myelodysplastic syndrome will be discussed in this review...
  57. ncbi request reprint Iron overload in myelodysplastic syndromes: diagnosis and management
    Alan F List
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 17:2-8. 2010
    ..This review presents the data related to iron overload in MDS, including its prevalence, diagnosis, clinical impact, and management...
  58. doi request reprint Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
    Dana E Rollison
    Cancer Prevention and Control Division, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Blood 112:45-52. 2008
    ..MDS incidence rates significantly increased with calendar year in 2001 through 2004, and only 4% of patients were reported to registries by physicians' offices. Thus, MDS disease burden in the United States may be underestimated...
  59. doi request reprint Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome
    Mohamed A Kharfan-Dabaja
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Biol Blood Marrow Transplant 17:384-93. 2011
    ..These results support day 90 hypoalbuminemia as an adverse prognostic marker for NRM and OS after allo-HCT for acute myelogenous leukemia and myelodysplastic syndrome...
  60. doi request reprint Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT)
    Yukiyasu Ozawa
    Experimental Therapeutics, H Lee Moffitt Cancer and Research Institute, Tampa, FL 33612, United States
    Leuk Res 32:893-903. 2008
    ..These data indicate that Src-STAT5 and Src-Akt pathways are integral survival signal pathways in AML cells. Src inhibition may represent a novel treatment strategy for investigation in AML...
  61. ncbi request reprint Histone deacetylase inhibitors in myelodysplastic syndrome
    Kapil Bhalla
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, MRC 3 East Room 3056, Tampa, FL 33614, USA
    Best Pract Res Clin Haematol 17:595-611. 2004
    ..In particular, hydroxamic acid-based polar compounds and cyclic tetrapeptides have shown activity against cancers at well-tolerated doses...
  62. pmc Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors
    Pearlie K Epling-Burnette
    Immunology Program, H Lee Moffitt Cancer Center, MRC 3 West, Tampa, FL 33612, USA
    Blood 109:4816-24. 2007
    ..Evasion of NK immunosurveillance may have importance for MDS disease progression...
  63. ncbi request reprint Lenalidomide--the phoenix rises
    Alan F List
    N Engl J Med 357:2183-6. 2007
  64. ncbi request reprint Cytokine targets in the treatment of myelodysplastic syndromes
    Amit Verma
    Department of Medicine Oncology, Albert Einstein Cancer Center, Chanin 601, Bronx, NY 10461, USA
    Curr Hematol Rep 4:429-35. 2005
    ....
  65. ncbi request reprint The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 30:801-11. 2006
    ..AG-01736 had minimal biologic or clinical activity in this elderly patient population...
  66. pmc Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS
    Li Zhou
    Albert Einstein College of Medicine, Bronx, NY, USA
    Blood 112:3434-43. 2008
    ..These data directly implicate TGF-beta signaling in the pathobiology of ineffective hematopoiesis and identify TBRI as a potential therapeutic target in low-risk MDS...
  67. ncbi request reprint Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
    Azra Raza
    Rush University Medical Center, Chicago, IL, USA
    Blood 111:86-93. 2008
    ..Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1-risk MDS who lack the deletion 5q karyotypic abnormality...
  68. ncbi request reprint Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes
    Gary J Schiller
    UCLA Division of Hematology Oncology, University of California Los Angeles, San Diego, CA 90095, USA
    J Clin Oncol 24:2456-64. 2006
    ..To evaluate the efficacy and safety of arsenic trioxide monotherapy in patients with myelodysplastic syndromes (MDS)...
  69. ncbi request reprint Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States
    Thomas F Goss
    Covance Market Access Services Inc, Gaithersburg, MD 20878, USA
    Cancer Control 13:17-25. 2006
    ..Confirmation of these findings awaits results of an ongoing randomized phase III trial (MDS-004 study)...
  70. ncbi request reprint Lenalidomide: from bench to bedside (part 1)
    Alan F List
    Cancer Control 13:2-3. 2006
  71. ncbi request reprint Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies
    Daruka Mahadevan
    University of Arizona Cancer Center, Tucson, AZ 85724, USA
    Blood 104:1940-51. 2004
    ..Lessons learned from investigations of these and other mechanisms of cellular defense hold promise for a renaissance in the development of targeted therapeutics in acute leukemia...
  72. ncbi request reprint Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture
    Joseph M Unger
    Southwest Oncology Group Statistical Center and the Puget Sound Oncology Consortium, Seattle, WA, USA
    J Clin Oncol 21:246s-252s. 2003
    ..Meanwhile the prevention of cancer has received less attention...
  73. ncbi request reprint Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity
    David P Steensma
    Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:681-98. 2005
    ....
  74. ncbi request reprint Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia
    Thomas Pabst
    Institute of Medical Oncology, University Hospital, Berne, Switzerland
    Br J Haematol 133:400-2. 2006
    ..Here, no CEBPA mutation in 95 CML-BC patients was found, suggesting a limited role, if any, of CEBPA mutations in this disorder...
  75. ncbi request reprint PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia
    Francis J Giles
    The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 31:891-7. 2007
    ..One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM...
  76. ncbi request reprint Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
    Azim Mohamedali
    Department of Haematological Medicine, King s College Hospital, King s College London School of Medicine, Denmark Hill, London, United Kingdom
    Blood 110:3365-73. 2007
    ..001). We show, for the first time, that SNP microarray analysis in low-risk MDS patients reveals hitherto unrecognized UPD and CN changes that may allow stratification of these patients for early therapeutic interventions...